Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
45.33
-0.28 (-0.61%)
Aug 31, 2026, 4:00 PM EDT - Market closed
Revenue
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 |
Rybelsus Revenue | 5.23B | |||||||||||||||||||||||
Ozempic Revenue | 31.38B | |||||||||||||||||||||||
Victoza Revenue | 181.00M | |||||||||||||||||||||||
Total GLP-1 Revenue | 36.78B | |||||||||||||||||||||||
Long-Acting Insulin Revenue | 4.41B | |||||||||||||||||||||||
Premix Insulin Revenue | 2.79B | |||||||||||||||||||||||
Fast-Acting Insulin Revenue | 4.69B | |||||||||||||||||||||||
Human Insulin Revenue | 1.05B | |||||||||||||||||||||||
Total Insulin Revenue | 12.94B | |||||||||||||||||||||||
Other Diabetes Care Revenue | 704.00M | |||||||||||||||||||||||
Total Diabetes Care Revenue | 50.43B | |||||||||||||||||||||||
Wegovy Revenue | 22.70B | |||||||||||||||||||||||
Saxenda Revenue | 450.00M | |||||||||||||||||||||||
Total Obesity Care Revenue | 23.15B | |||||||||||||||||||||||
Diabetes & Obesity Care Revenue | 73.58B | |||||||||||||||||||||||
Rare Blood Disorders Revenue | 2.90B | |||||||||||||||||||||||
Rare Endocrine Disorders Revenue | 1.54B | |||||||||||||||||||||||
Other Rare Disease Revenue | 473.00M | |||||||||||||||||||||||
Rare Disease Revenue | 4.91B | |||||||||||||||||||||||
Revenue (Total) | 78.49B |
Revenue by Geography
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 |
US Revenue | 40.87B | |||||||||||||||||||||||
EUCAN Revenue | 19.21B | |||||||||||||||||||||||
Emerging Markets Revenue | 8.41B | |||||||||||||||||||||||
APAC Revenue | 5.03B | |||||||||||||||||||||||
China Revenue | 4.97B | |||||||||||||||||||||||
Total International Revenue | 37.62B | |||||||||||||||||||||||
Revenue (Other) | -37.62B | |||||||||||||||||||||||
Revenue (Total) | 78.49B |
EBIT
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 |
Diabetes & Obesity Care Operating Profit | 28.36B | |||||||||||||||||||||||
Rare Disease Operating Profit | -1.30B | |||||||||||||||||||||||
Operating Income (Total) | 27.06B |